Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess margin positive resection rate (R1 resection rate; defined as "tumor within 2 mm of
surgical margin on final pathology report") in patients treated with preoperative
chemotherapy (gemcitabine and erlotinib) with or without external-beam radiation therapy
followed by pancreaticoduodenectomy for adenocarcinoma of the pancreatic head.
Secondary Objectives:
- To assess disease free survival
- To assess overall survival
- To assess patterns of local and distant failure